about
Metabolism of kidney cancer: from the lab to clinical practiceDendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiencyLow CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinomaManagement of acute prostatitis, based on a series of 100 casesReassessing the current UICC/AJCC TNM staging for renal cell carcinoma.Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience.Prognostic value of thrombocytosis in renal cell carcinoma.Prognostic ability of simplified nuclear grading of renal cell carcinoma.Renal cell carcinoma guideline.Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC).Renal cell carcinoma in young adults: incidence, disease outcome and review of the literature.The current status of intravesical therapy for superficial bladder cancer.Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitroThe conserved transcriptome in human and rodent male gametogenesisUnderstanding the importance of smart drugs in renal cell carcinoma.Transperitoneal laparoscopic nephrectomy for autosomal dominant polycystic kidney disease.Prognostic factors and selection for clinical studies of patients with kidney cancer.Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy.Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.Update on the medical treatment of metastatic renal cell carcinoma.New therapies in renal cell carcinoma.Incidental renal tumours.Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.Survival of patients with nonmetastatic pT3 renal tumours: a matched comparison of laparoscopic vs open radical nephrectomy.Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.Nephron sparing surgery for renal angiomyolipoma with inferior vena cava thrombus in tuberous sclerosis.Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?EAU guidelines on renal cell carcinoma: the 2010 update.Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer.Kidney cancer in 2010: drugs, surgery and survival in RCC.ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.Lymph node dissection in renal cell carcinoma.Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?Optimizing treatment for metastatic renal cell carcinoma.Positive surgical margins after nephron-sparing surgery.The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.Relationship between surgical volume and outcomes in nephron-sparing surgery.T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept.Loss of expression of TIMP3 in clear cell renal cell carcinoma.
P50
Q24600512-A64936C4-316C-4E25-BD25-68850DB9616FQ24810259-C4802C68-150A-46E9-9A46-E1659B2DE8D4Q27851432-CB0690AC-C236-4367-80EF-57A1169D29D9Q28244461-4215289C-964D-4360-BEB2-1072C16BFE88Q33481408-E58E1E75-741B-40C6-BDA0-B5F042E29BDEQ34547619-3A6F5533-7805-4371-BB76-992A98867C05Q34564760-1DEC74F3-D3F9-4414-AF3F-92A7CB8CFF2EQ34574526-327BA24D-4B1B-4D5B-9338-2FCA6FDAE99DQ34615846-F70D1EB7-8F51-4A60-A924-16D56B55F6C4Q34778993-0F6FBF0C-F935-475C-B23F-454773B931BDQ35010605-39CCA4C0-3B9F-4746-B21C-5D8C76AD0348Q35199096-973B8DFC-CFE2-47A4-AD05-5A9262AE7A68Q35569867-99953DBF-D662-44D7-87D5-4C9E80577EDFQ35781510-E03E4FE4-9B13-4194-AD8F-C71B3D5E3B7AQ36397654-0F4A2AF8-A2AF-4253-8708-BBA83DE59365Q36504994-AC2C0652-92CA-4EA5-96FB-1F691C5A0CF1Q36968662-327ACF56-BCFE-49A5-BBBF-BA9EB374C0D4Q36995364-4B7BC717-BD3E-4664-89AE-97A5340BBDDAQ37022440-E947AE66-6362-4442-94AC-12CDE5302259Q37165968-3D5BEA1A-B1C8-49A0-9E05-F5903463236DQ37237026-DBA104FC-7D58-4AB4-9480-ABD8A001AFC2Q37538479-7282DAF5-C4A8-452A-8220-C713F8E7B636Q37556918-2C02AD95-32AA-4BE2-94B1-225727F3FD12Q37558644-12391DD2-D7C0-491F-ADC6-B53BA5AA3197Q37578693-6B63FAB9-701F-43EE-9671-AA9550DC6146Q37689617-E552DC50-5EEB-40ED-AEBE-27943112BF17Q37772190-401C5D13-99F3-4026-8198-C0C8B4946CCBQ37773064-A4F846A3-DA2C-4BAA-A3B1-ADB04F769A28Q37786720-1F0128BE-A623-4421-99C2-5D2FD14E6F83Q37811705-E115CE20-3F62-402B-94BC-1EB60D3C97FEQ37838249-B2D26C05-CD62-401C-9341-6ABC503D4F71Q37894362-C9033C95-9A32-45E0-A5FD-7EA41AF33B3DQ37937206-C5E3CB14-8DA5-4C4E-9D5C-A2D76AB049BBQ37953000-3AEF60A4-806A-497A-A71A-34AB03AEDFB7Q37960915-DC0ADB90-C43D-4FFD-BC27-FC081280E670Q37964092-BA3E1C17-381A-45DC-809E-D3C6A97A1E07Q38094592-26FBF79A-3F52-4AC4-B1B0-07BE0AEB83F6Q38216764-42318D5A-39F2-4447-95E3-6CE6854F0C55Q38294442-C80C259A-D479-4052-BFB9-DC23B5598646Q38417621-505AD2DC-BF22-4B66-9B2C-27907343C05F
P50
name
Jean-Jacques Patard
@ast
Jean-Jacques Patard
@en
Jean-Jacques Patard
@nl
type
label
Jean-Jacques Patard
@ast
Jean-Jacques Patard
@en
Jean-Jacques Patard
@nl
prefLabel
Jean-Jacques Patard
@ast
Jean-Jacques Patard
@en
Jean-Jacques Patard
@nl
P214
P21
P214
P31
P7859
viaf-172336836